^
    Back
    Association details:
    Biomarker:MDM2 amplification
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Br J Haematol
    Title:

    Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

    Published date:
    10/10/2021
    Excerpt:
    Here we analysed clinico-biological features in 373 DLBCL patients homogeneously treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP), in order to identify variables associated with early failure to treatment (EF)...Mutations in NOTCH2, gains in 5p15·33 (TERT), 12q13 (CDK2), 12q14·1 (CDK4) and 12q15 (MDM2) showed predictive importance for EF independently from R-IPI.
    DOI:
    10.1111/bjh.17858